Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 116

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 116
---
 United States. In addition, awards of punitive damages in actions brought in the United States or
elsewhere may be unenforceable in England. An award of damages is usually considered to be punitive if it does not seek to compensate
the claimant for loss or damage suffered and is instead intended to punish the defendant. In addition to public policy aspects of enforcement,
such as the aforementioned, the enforceability of any judgment in England will depend on the particular facts of the case and the relevant
circumstances, for example (and expressly without limitation), whether there are any relevant insolvency proceedings which may affect
the ability to enforce a judgment. In addition, the United States and the United Kingdom have not currently entered into a treaty (or
convention) providing for the reciprocal recognition and enforcement of judgments (although both are contracting states to the New York
Convention on the Recognition and Enforcement of Foreign Arbitral Awards).

| 76 |

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We are subject to periodic reporting and
other informational requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as applicable to foreign private
issuers. Accordingly, we are required to file reports, including annual reports on Form 20-F, and other information with the SEC. As a
foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to
shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and our “insiders”
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. The SEC maintains
an Internet site that contains reports, proxy, information statements and other information regarding issuers at http://www.sec.gov. Copies
of certain information filed by us with the SEC are also available on our website at http://www.biodexapharma.com. Our website is not
a part of this prospectus and is not incorporated by reference in this prospectus.

This prospectus is part of a registration
statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC
rules and regulations. You should review the information and exhibits in the registration statement for further information on us and
our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an
exhibit to the registration statement or